Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

211 Mt. Airy Road
Basking Ridge, NJ 07920

Tel: (908) 992-6400

Visit website

NEWS

Policy

FDA Accepts BLA for AstraZeneca, Daiichi Sankyo’s ADC for NSCLC

The companies’ Biologics License Application for antibody-drug conjugate datopotamab deruxtecan has been accepted by the FDA for locally advanced or metastatic nonsquamous non-small cell lung cancer.

February 19, 2024

2 min read

Tyler Patchen

Pictured: Bar and line graphs showing increasing t

Business

Daiichi Sankyo Again Raises Enhertu Sales Forecast Driven by Non-US Growth

Buoyed by its strong performance outside of the U.S. market, Daiichi Sankyo on Wednesday again raised its sales expectations for the blockbuster antibody-drug conjugate.

February 1, 2024

2 min read

Tristan Manalac

Pictured: AstraZeneca signage at its office in Sweden

Policy

AstraZeneca, Daiichi’s Enhertu Given FDA Priority Review for Metastatic HER2 Positive Solid Tumors

The FDA has granted Priority Review for AstraZeneca and Daiichi Sankyo’s supplemental BLA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors.

January 30, 2024

2 min read

Tyler Patchen

Pictured: Facade of the U.S. Patent and Trademark

Policy

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo

The U.S. Patent and Trademark Office has sided with Daiichi over Seagen in a years-long patent saga concerning a key linker technology used in its blockbuster Enhertu antibody-drug conjugate for cancer.

January 17, 2024

2 min read

Tristan Manalac

Pictured: A wooden gavel on a table with a book in

Policy

Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit

Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.

January 4, 2024

2 min read

Tyler Patchen

Policy

Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case

Plexxikon, which was acquired by Daiichi Sankyo, and Novartis have agreed to settle a patent case involving the cancer drug Tafinlar and its sale in the U.S.

December 8, 2023

1 min read

Tyler Patchen

Pictured: 3D illustration of antibody-drug conjugates carrying toxic payloads

Drug Development

AstraZeneca, Daiichi Address Safety Concerns for DXd ADC at ESMO

The companies presented data from two pivotal studies of Dato-DXd, focusing on safety concerns and survival data for the investigational antibody-drug conjugate candidate in lung and breast cancer.

October 24, 2023

2 min read

Tristan Manalac

Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads

Business

Biopharma Industry Continues to Bet Big on Antibody-Drug Conjugates

While Merck lost out to Pfizer earlier this year in snapping up Seagen, this week the company closed a deal worth a potential $22 billion with Daiichi Sankyo—further evidence of the industry’s insatiable appetite for ADC technology.

October 20, 2023

2 min read

Greg Slabodkin

Pictured: Merck building and sign in Silicon Valley

Business

Merck Pays $4B Upfront for Daiichi Sankyo’s DXd-Based ADCs

Seeking to deepen its immuno-oncology business, Merck has closed a deal potentially worth $22 billion across three of Daiichi Sankyo’s DXd antibody-drug conjugates for various solid tumor indications.

October 20, 2023

2 min read

Tristan Manalac

JOBS